X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9) 9
female (7) 7
humans (7) 7
respiratory system (6) 6
male (5) 5
pulmonary/respiratory (5) 5
chemotherapy (4) 4
lung cancer (4) 4
lung neoplasms - pathology (4) 4
oncology (4) 4
abridged index medicus (3) 3
aged (3) 3
cancer therapies (3) 3
critical care medicine (3) 3
endothelial growth-factor (3) 3
lung neoplasms - drug therapy (3) 3
medical prognosis (3) 3
middle aged (3) 3
mutation (3) 3
research (3) 3
adult (2) 2
aged, 80 and over (2) 2
angiogenesis inhibitor (2) 2
bevacizumab (2) 2
biopsy, needle (2) 2
cancer (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
clinical trials (2) 2
cooperative-oncology-group (2) 2
immunotherapy (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - genetics (2) 2
lung neoplasms - mortality (2) 2
mesothelioma (2) 2
metastasis (2) 2
nsclc (2) 2
open-label (2) 2
patients (2) 2
plus bevacizumab (2) 2
product development (2) 2
prognostic-factors (2) 2
1st-line therapy (1) 1
1st-line treatment (1) 1
acute respiratory-failure (1) 1
adenocarcinoma (1) 1
adenocarcinoma of lung - complications (1) 1
adenocarcinoma of lung - drug therapy (1) 1
adenocarcinoma of lung - secondary (1) 1
adolescent (1) 1
adrenal gland neoplasms - secondary (1) 1
analysis (1) 1
angiogenesis inhibitors (1) 1
anti-bacterial agents - therapeutic use (1) 1
antibiotic-therapy (1) 1
antibiotics (1) 1
antibodies (1) 1
antineoplastic agents, immunological - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
asbestos (1) 1
bacterial pneumonia (1) 1
bacterial typing techniques (1) 1
bevacizumab - administration & dosage (1) 1
bevacizumab - adverse effects (1) 1
biopsy, needle - instrumentation (1) 1
blocking antibodies (1) 1
breast cancer (1) 1
bronchoalveolar lavage (1) 1
cancer patients (1) 1
cancer-patients (1) 1
carboplatin (1) 1
carcinoma, non-small-cell lung - diagnosis (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, non-small-cell lung - physiopathology (1) 1
care and treatment (1) 1
care-associated pneumonia (1) 1
case report (1) 1
cell division (1) 1
cisplatin (1) 1
cisplatin - administration & dosage (1) 1
cisplatin - adverse effects (1) 1
clinical-outcomes (1) 1
co-morbidity (1) 1
colorectal cancer (1) 1
combination (1) 1
contamination (1) 1
creatinine - blood (1) 1
crizotinib (1) 1
crizotinib - therapeutic use (1) 1
cross infection - diagnosis (1) 1
cross infection - drug therapy (1) 1
cross infection - microbiology (1) 1
cysts (1) 1
cytotoxicity (1) 1
deoxycytidine - administration & dosage (1) 1
deoxycytidine - adverse effects (1) 1
deoxycytidine - analogs & derivatives (1) 1
development and progression (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
Chest, ISSN 0012-3692, 2011, Volume 140, Issue 1, pp. 265 - 266
Journal Article
Respiratory Care, ISSN 0020-1324, 02/2016, Volume 61, Issue 2, pp. 225 - 234
Journal Article
Lung Cancer, ISSN 0169-5002, 2010, Volume 70, Issue 3, pp. 301 - 307
Journal Article
La Presse Medicale, ISSN 0755-4982, 2006, Volume 35, Issue 9, pp. 1387 - 1400
est, dans notre expérience comme dans celle de bien d’autres centres, l’indication la plus fréquente de la TEP au FDG (fluorodésoxyglucose). dans la... 
Journal Article
Future Oncology, ISSN 1479-6694, 12/2017, Volume 13, Issue 28, pp. 2515 - 2535
Despite recent advances in metastatic lung cancer treatment with the advent of immune checkpoint inhibitors and molecules targeting addictive genomic... 
lung cancer | bevacizumab | angiogenesis inhibitor | 1ST-LINE TREATMENT | PLACEBO-CONTROLLED-TRIAL | MAINTENANCE BEVACIZUMAB | OPEN-LABEL | ONCOLOGY | RANDOMIZED PHASE-II | PLATINUM-BASED CHEMOTHERAPY | DOUBLE-BLIND | PACLITAXEL PLUS CARBOPLATIN | ENDOTHELIAL GROWTH-FACTOR | COOPERATIVE-ONCOLOGY-GROUP
Journal Article
Future Oncology, ISSN 1479-6694, 12/2017, Volume 13, Issue 28, pp. 2537 - 2546
Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for themajority of... 
bevacizumab | malignant pleural mesothelioma | angiogenesis inhibitor | FORTHCOMING 8TH EDITION | PROGNOSTIC-FACTORS | TNM CLASSIFICATION | OPEN-LABEL | PHASE-II TRIAL | CANCER-PATIENTS | ONCOLOGY | STAGING PROJECT PROPOSALS | IASLC MESOTHELIOMA | PLUS BEVACIZUMAB | ENDOTHELIAL GROWTH-FACTOR
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.